Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies 15th January 2021 Boehringer Ingelheim has entered a strategic collaboration with UK biotech Enara Bio to research and discover novel targeted cancer immunotherapies. The agreement will leverage Enara’s Dark Antigen discovery platform to identify and validate novel dark antigens in up to three tumour types across the lung and gastrointestinal cancer areas. Dark antigens are a new class of cancer-associated antigens that derive from genomic dark matter – the portion of the human genome that is normally not ex...
Source: pharmatimes.com